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Advanced glycation end product (AGE) formation
may contribute to the progression of atherosclerosis,
particularly in diabetes. The present study explored
atherosclerosis in streptozotocin-induced diabetic apo-
lipoprotein E–deﬁcient (apoE/) mice that were ran-
domized (n  20) to receive for 20 weeks no treatment,
the AGE cross-link breaker ALT-711, or the inhibitor of
AGE formation aminoguanidine (AG). A sixfold in-
crease in plaque area with diabetes was attenuated by
30% with ALT-711 and by 40% in AG-treated mice.
Regional distribution of plaque demonstrated no reduc-
tion in plaque area or complexity within the aortic arch
with treatment, in contrast to the thoracic and abdom-
inal aortas, where signiﬁcant attenuation was seen.
Diabetes-associated accumulation of AGEs in aortas
and plasma and decreases in skin collagen solubility
were ameliorated by both treatments, in addition to
reductions in the vascular receptor for AGE. Collagen-
associated reductions in the AGEs carboxymethyllysine
and carboxyethyllysine were identiﬁed with both treat-
ments. Diabetes was also accompanied by aortic accu-
mulation of total collagen, speciﬁcally collagens I, III,
and IV, as well as increases in the proﬁbrotic cytokines
transforming growth factor- and connective tissue
growth factor and in cellular -smooth muscle actin.
Attenuation of these changes was seen in both treated
diabetic groups. ALT-711 and AG demonstrated the
ability to reduce vascular AGE accumulation in addition
to attenuating atherosclerosis in these diabetic mice.
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M
acrovascular complications develop in 50%
of the diabetic population and account for
50–60% of the mortality in this high-risk
population (1). Dyslipidemia, hypertension,
and hyperglycemia all play a role in the development of
diabetes-associated atherosclerosis (2), although the spe-
ciﬁc contributions from each of these independent risk
factors remains controversial.
The in vivo relevance of the Maillard reaction and the
subsequent production of advanced glycation end prod-
ucts (AGEs) in the macrovascular complications of diabe-
tes was ﬁrst emphasized in studies using the inhibitor
advanced glycation aminoguanidine (AG) (3). Subsequent
studies that used exogenous administration of AGEs to
mimic diabetic serum concentrations indicated that AGEs
could induce atherosclerosis (4). Furthermore, AGEs in-
teract with endothelial cells to induce the expression of
atherogenic adhesion molecules implicated in atherogen-
esis (5,6).
More recently, the contribution of not only AGEs
formed in the presence of both oxygen and sugar, namely
glycoxidation products, but those derived from lipoxida-
tion (7) or advanced lipoxidation end products (ALEs) to
diabetic vascular complications has been suggested (8).
Studies in experimental obese Zucker rats, a model of
insulin resistance with the AGE formation inhibitor pyri-
doxamine, have shown marked attenuation of the charac-
teristic hyperlipidemia, reduced ALEs, and hypertension,
indicating interactions between AGEs and lipids (9). The
role of these ALEs in atherosclerosis, a disease process
linked not only to hyperglycemia but also to dyslipidemia
is yet to be elucidated.
One of the seminal in vivo studies performed in exper-
imental diabetes-associated atherosclerosis demonstrated
attenuation of plaque formation with the soluble receptor
for AGEs (sRAGE) (10). It should be noted that RAGE
interacts with a range of other molecules in addition to
AGEs, such as amphoterin and S-100 (11), which could
themselves participate in the atherosclerotic process.
Therefore, it remains unresolved as to whether the anti-
atherosclerotic effects of sRAGE are primarily related to
its effects in inhibiting AGE-mediated events or via other
mechanisms, although the former remains the most likely.
AG is the most extensively studied of the AGE formation
inhibitors and has previously been shown to attenuate
vascular complications (3). More recently, another thera-
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DIABETES, VOL. 53, JULY 2004 1813peutic approach has involved the use of a thiazolium
derivative ALT-711, a compound that is suggested to be
capable of breaking AGE cross-links, thereby removing
preformed AGEs (12). ALT-711 has proved successful as
an intervention therapy in established diabetic microvas-
cular complications (13,14) and has also been reported to
improve vascular compliance in aging humans (15). Other
studies in the diabetic context have shown that ALT-711
attenuates both cardiac (14) and renal (13) accumulation
of AGEs in association with beneﬁts on renal and cardiac
injury. Therefore, the present study examined the effects
of ALT-711 and compared it with the more traditional AGE
formation inhibitor AG in a well-characterized model of
diabetes-associated atherosclerosis (10,16), the streptozoto-
cin-induced diabetic apolipoprotein E–deﬁcient (apoE/)
mouse. Plaque area, complexity, and ﬁbrosis in the aorta
were examined in the presence and absence of these
treatments. Collagen solubility and expression were also
assessed with emphasis placed on both ﬁbrillar and mem-
branous collagens. Finally, AGE and ALE accumulation
and expression of RAGE were evaluated.
RESEARCH DESIGN AND METHODS
Experimental model. Six-week-old homozygous apoE-deﬁcient male mice
(backcrossed 20 times from C57BL/6 background; Animal Resource Centre,
Canning Vale, WA, Australia) were studied in accordance with guidelines
provided by the Alfred and Baker Animal Ethics Committee. Mice were
rendered diabetic by daily injection of streptozotocin at a dosage of 55 mg/kg
for 5 consecutive days. Control animals were given daily injections of vehicle
(citrate buffer) alone. Groups of diabetic animals (n  20/group) were then
randomized after 1 week of recovery to receive 1) no treatment; 2) AGE
cross-link breaker ALT-711 [4,5-dimethyl-3-(2-oxo2-phenylethyl)-thiazolium
chloride; Alteon, Ramsey, NJ], gavaged at 10 mg  kg
1  day
1 (DALT); or 3)
the AGE formation inhibitor AG hydrocarbonate (Fluka Pharmaceuticals) at
200 mg  kg
1  day
1 (DAG; 1 g/l in drinking water). All groups of animals were
followed for 20 weeks. Mice were allowed access to standard mouse diet and
water ad libitum. An initial pilot study using two doses of ALT-711 (gavaged at
10 or 20 mg  kg
1  day
1) revealed no differences between the two doses in
terms of the primary end point of plaque accumulation or aortic AGE
accumulation. Therefore, the deﬁnitive study involving comparison with AG
was performed using 10 mg  kg
1  day
1 ALT-711.
At the conclusion of the study, glycated Hb (GHb) was measured by
high-performance liquid chromatography (17). Total cholesterol, HDL, and
triglyceride concentrations were measured by autoanalyzer. LDL cholesterol
was calculated by the Friedewald formula (18). Systolic blood pressure was
assessed by a computerized, noninvasive tail-cuff technique in conscious mice
(19).
After 20 weeks, after anesthesia with intraperitoneal pentobarbital sodium
(60 mg/kg body wt; Nembutal, Boehringer Ingelheim, Mannheim, Germany),
aortas were rapidly dissected and snap-frozen in liquid nitrogen. A subset of
aortas from each group (n  10 mice per group) were removed and ﬁxed in
neutral-buffered formalin for subsequent evaluation of lesions.
Evaluation of atherosclerotic lesion area. Two approaches were used to
evaluate the atherosclerotic lesions as described previously (16). First,
macroscopic assessment of en face whole aorta segments was performed. The
entire aorta was cleaned of fat, opened longitudinally, and dissected into three
segments: aortic arch, descending thoracic aorta, and abdominal aorta. After
staining with Sudan IV-Herxheimer’s solution (Sigma Chemical Co, Carpinte-
ria, CA), aortas were pinned out ﬂat, and images were digitized on a dissecting
microscope (Olympus SZX9; Olympus Optics, Tokyo, Japan) equipped with a
high-resolution camera (Zeiss Axiocam; Zeiss Instruments, Gottingen, Ger-
many). The digitized images were evaluated, and the lesion area was evaluated
by calculation of the proportion of aortic intimal surface occupied by red stain
in each of the three aortic segments using Image SXM program software
(National Institutes of Health, Bethesda, MD).
The aortic segments studied above were then embedded in parafﬁno ne n d
and cross-sectioned at 4 m for subsequent immunohistochemistry, in situ
hybridization, and histological evaluation. Secondary histological assessment
of lesions was performed on sections stained with Masson’s Trichrome as
described previously (16). Total collagen was quantiﬁed by calculation of the
area of aniline blue staining occupied within the plaques by Optimas 6.2
Software (Optimas 6.2; Video Pro-32, Bedford Park, SA, Australia) associated
with a JVC video camera and Olympus microscope.
Plasma AGE peptide analysis. Fluorescence was assayed in duplicate 20-l
plasma aliquots as described previously (13). Characteristic ﬂuorescence
(excitation 370 nm, emission 440 nm) has been previously attributed to the
accumulation of AGE cross-links (20,21). Brieﬂy, samples were deproteinated
and delipidated by addition of 0.15 mol/l trichloroacetic acid and chloroform
(22), followed by centrifugation and removal of the upper aqueous phase.
Fluorescence of the supernatant was determined (excitation 370 nm, emission
440 nm) using an on-line high-performance liquid chromatography injector
(Waters, Milford, MA) and expressed per arbitrary protein unit at 280 nm.
Isolation of skin collagen and analysis of AGEs/ALEs. Mouse skin
collagen was prepared as described previously for rat skin collagen (8). In
brief, insoluble collagen was isolated from 1.5-cm pieces of skin after removal
of fat and hair with a razor blade and subsequent sequential extractions with
1.0 mol/l NaCl, 0.5 mol/l acetic acid, and delipidation with chloroform:
methanol (1:2). The collagen was then lyophilized and stored at 20°C until
analyzed for AGE/ALE content. The AGEs/ALEs N(carboxymethyl)lysine
(CML) and N(carboxyethyl)lysine (CEL) were quantiﬁed by isotope dilution
and selected ion monitoring gas chromatography–mass spectrometry (23) and
normalized to their parent amino acid lysine.
Evaluation of cross-linking. Skin collagen (3 mg), prepared as above, was
used for cross-linking analysis and added to 7.5 ml of 0.5 mmol/l acetic acid
containing 10 mol/l pepsin (Sigma Chemical Co.) and incubated at 37°C with
gentle agitation (60 Hz). Aliquots of 250 l were removed at 0, 4, 8, 12, 16, and
24 h of digestion. The conditions were chosen on the basis of preliminary
studies that showed signiﬁcant solubilization of collagen from nondiabetic
animals at 1 h and maximum solubilization (98%) after 24 h. The collagen
content of these samples was determined after acid hydrolysis (6 mol/l HCl for
2 4ha t1 1 0 °C) using the procedure of Stegemann and Stadler (24). Collagen
solubility was expressed as a function of time with the 0 time point providing
0% digestion and the 24-h time point providing 100% digestion. The collagen
content at each time point of pepsin digestion was expressed as a percentage
of the total recoverable collagen after 24 h. The time taken for digestion of 50%
of the collagen was determined for each of the groups using derivatization of
area under the curve.
Skin ﬂuorescence (at excitation 370 nm, emission 440 nm) was determined
in 24-h acid-hydrolyzed collagen preparations in the presence of 0.1 mol/l
NaBH4, via a ﬂow injection system adapted from Wrobel et al. (22) using a
Waters 470 spectrophotometer/ﬂuorometer (Waters). For correcting for dif-
ferences in sample collagen content, ﬂuorescence intensity was expressed as
arbitrary units of ﬂuorescence per milligram of collagen.
Immunohistochemistry. A modiﬁcation of the ABC Ig enzyme bridge
technique (25) was used for immunohistochemistry. Formalin-ﬁxed parafﬁn
sections of aortas from previous en face studies were dewaxed and hydrated.
Antigen retrieval by microwaving in citrate buffer (1.8 mmol/l citric acid, 8.2
mmol/l trisodium citrate) twice for 5 min was performed for connective tissue
growth factor (1:500; rabbit anti-rCTGF; gift of Dr. S. Twigg, Department of
Medicine, University of Sydney) (26) and transforming growth factor-
(TGF-; 1:250; Santa Cruz Biotechnology, Santa Cruz, CA). Slides for collagen
immunostaining were porcine pepsin digested (0.4%) in 0.5% nonfat milk
powder diluted in Tris-buffered saline containing 0.05% Tween 20. After
incubation with 0.3% hydrogen peroxide for 20 min, sections were incubated
with protein-blocking agent (Lipshaw, Pittsburgh, PA) for 20 min and then
incubated with primary antibody overnight at 4°C. CML is the major epitope
recognized by the monoclonal anti-AGE antibody, 4G9, used in this protocol
(1:500, Alteon) (27). Other primary antibodies used were polyclonal goat
anti-RAGE (1:250; Chemicon, Temecula, CA); goat anti-human collagen I, III,
and IV (1:80, 1:75, and 1:800, respectively; Southern Biotechnologies, Birming-
ham, AL); and mouse anti-human -smooth muscle actin (-SMA; 1:50; Dako).
Tissue sections were stained consecutively with biotinylated IgG for 10 min
and avidin-biotin horseradish peroxidase complex for 15 min (Vectastain ABC
ELITE kit; Vector Laboratories, Burlingame, CA) before a substrate solution of
3,3-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) was added.
Sections were counterstained in Harris’ hematoxylin and mounted in dePex
(BDH; Merck, Poole, U.K.). Negative control sections had the omission of the
primary antibody. Positive control tissues were also included. Quantiﬁcation
of aortic cross-section immunostaining was completed by computer-aided
densitometry (Optimas 6.2; Video Pro-32), whereby a total of 10 slides that
contained at least 6 sections (	100) per group were counted. Results were
expressed as proportional area of positive staining (28) in cross-sections.
In situ hybridization. Localization of CTGF mRNA was determined by in
situ hybridization as previously described, with the inclusion of a sense
riboprobe to determine background hybridization (16). Brieﬂy, antisense
CTGF and sense riboprobes labeled with
35S CTP were prepared using the
Promega Transcription System (Promega, Madison, WI). Four-micron sec-
AGE INTERVENTION IN ATHEROSCLEROSIS
1814 DIABETES, VOL. 53, JULY 2004tions were incubated in 125 g/ml Pronase E at 37°C, postﬁxed in 4%
paraformaldehyde, and air dried. The slides were then incubated overnight at
60°C in hybridization buffer that contained 2 	 10
4 cpm/l
35S-labeled
riboprobe, 0.72 mg/ml yeast RNA, 50% deionized formamide, 100 mmol/l
dithiothreitol, 10% dextran sulfate, 0.3 mol/l NaCl, 10 mmol/l Na2HPO4 (pH
7.5), 5 mmol/l EDTA (pH 8.0), 0.02% BSA, 0.02% Ficoll 400, and 0.02%
polyvinylpyrrolidone. Coverslips were removed, and sections were rinsed and
then incubated at 37°Ci n1 5 0g/ml RNase A for 1 h. Samples were washed,
air dried, and exposed to BioMax MR ﬁlm for 3–5 days. For microscopic
localization, slides were coated in Amersham LM-1 emulsion, dried for 1 h, and
incubated at 4°C in a light-proof container with desiccant for a period of 2–4
weeks according to the autoradiography results and developed photographi-
cally as previously described.
Statistical analysis. Results are expressed as means 
 SE unless otherwise
speciﬁed. Analyses were performed by ANOVA followed by post hoc analysis
using Fischer’s least signiﬁcant difference method, correcting for multiple
comparisons (Statview V). P  0.05 was considered to be statistically
signiﬁcant.
RESULTS
Metabolic parameters. Plasma glucose and GHb were
increased in all diabetic animals as compared with the
control group (Table 1). There was a modest decrease in
GHb in AG-treated animals. Diabetic mice also had de-
creases in body weight, which were not affected by either
treatment (Table 1). Systolic blood pressure remained
unchanged between control and diabetic mice, although
there was a signiﬁcant reduction in blood pressure noted
in the DALT treatment group (Table 1). When compared
with untreated diabetic mice, those that were treated with
ALT-711 showed signiﬁcant reductions in plasma total
cholesterol, LDL cholesterol, and triglycerides. AG treat-
ment did not affect plasma triglycerides and had a modest
effect on HDL cholesterol, but no statistical changes were
seen with respect to total or calculated LDL cholesterol
(Table 1).
Atherosclerotic plaque Areas. En face analysis of total
aortic plaque area revealed an approximately sixfold in-
crease in the untreated diabetic as compared with control
mice (Fig. 1A). The lesions throughout the aortas of these
diabetic animals appeared complex and ﬁbrous as com-
pared with the control apoE/ animals, which seemed
to have mostly fatty streaks with complex plaques evident
only in the aortic arch. Both AG- and DALT-treated ani-
mals demonstrated signiﬁcant abrogation in total plaque
area and in the complexity of plaques. There was no
attenuation of plaque area seen in any treatment group in
the aortic arch region (Fig. 1B), and these lesions ap-
peared ﬁbrous and complex in all groups. By contrast, in
the thoracic and abdominal regions, complex plaques
were identiﬁed primarily in the untreated diabetic group.
Each of the treatments administered to diabetic animals
afforded a similar degree of attenuation in plaque lesion
area in both the thoracic (Fig. 1C) and abdominal (Fig. 1D)
regions of the aorta.
Plasma content and aortic expression of AGEs and
RAGE. Diabetes induced a modest but signiﬁcant increase
in plasma AGE peptides (Fig. 2A). These diabetes-induced
increases were completely prevented by each of the
treatments.
Immunohistochemical analysis of the nonﬂuorescent
AGE CML in aortic cross-sections revealed signiﬁcant
increases in the untreated diabetic group (Fig. 2B and 3A).
There was extensive CML staining localized within the
vascular wall, particularly in smooth muscle cells as well
as in the endothelial and adventitial layers (Fig. 3B). There
was also CML staining within the cellular portion of
diabetic plaques. The elastic laminae, however, remained
unstained. The most effective attenuation of this vascular
wall staining of CML was seen in the DALT groups (Fig.
3C), although the AG-treated group also showed signiﬁ-
cant reductions in staining for CML (Fig. 3D). It is inter-
esting that there was still some CML immunostaining
identiﬁed within plaques of the DALT group.
Quantiﬁcation of RAGE expression by immunohisto-
chemistry identiﬁed a signiﬁcant increase in this receptor
in untreated diabetic mice as compared with control
apoE/ mice (Fig. 2C). RAGE was localized throughout
the aortic wall, particularly within the endothelium and
adventitia, although there was also staining evident within
the plaques of the untreated diabetic group (Fig. 3E and
F). Each of the treatments prevented the diabetes-induced
expression of RAGE within the aorta (Figs. 2C and 3G and
H). No immunostaining was evident in the negative con-
trol sections in which the primary antibody was omitted.
Skin collagen cross-linking and AGE/ALE analysis.
Skin collagen from diabetic animals was less soluble than
collagen taken from control animals. The time taken to
reach 50% digestion of the diabetic collagen with pepsin
was 8.4 h as compared with 3.8 h in control animals (Fig.
4A). Each of the apoE/ diabetic groups, which received
treatment, demonstrated increased solubility of their skin
collagen. The DALT and DAG groups showed similar
ﬁndings with 50% digestion achieved at 5 h in both
groups.
Skin collagen–associated CML was increased by diabe-
tes and was attenuated by both treatments, although AG
seemed to be more effective (Fig. 4B). There was no
TABLE 1
Metabolic parameters for all groups at week 20
Parameters Control Diabetes Diabetes  ALT-711 Diabetes  AG
n 20 20 20 20
GHb (%) 3.8 
 0.1 13.6 
 0.4* 14.1 
 1.2* 11.9 
 0.5*†
Body weight (g) 30.0 
 0.5 21.1 
 0.3* 22.0 
 1.0* 21.0 
 0.3*
Systolic blood pressure (mmHg) 117 
 2 118 
 5 104 
 4§ 125 
 6
Total cholesterol (mmol/l) 14.2 
 0.5 35.6 
 2.4* 22.0 
 3.6*§ 31.6 
 1.2*‡
HDL cholesterol (mmol/l) 4.5 
 0.2 8.2 
 0.7* 7.5 
 1.1* 6.5 
 0.3*§
LDL cholesterol (mmol/l) 9.2 
 0.3 26.1 
 1.5* 13.9 
 2.4§ 24.1 
 0.7*‡
Triglycerides (mmol/l) 0.9 
 0.1 1.9 
 0.3* 1.2 
 0.3† 2.0 
 0.3*‡
Data are means 
 SE except for GHb and body weight, which are means 
 SD. *P  0.001 vs. control group; †P  0.05 vs. diabetic group;
‡P  0.001 vs. diabetes  ALT group; §P  0.001 vs. diabetic group.
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collagen CEL to below control levels (Fig. 4C). Finally,
untreated diabetic skin collagen showed increased AGE
ﬂuorescence (excitation 370 nm, emission 440 nm) as
compared with control mouse skin collagen (Fig. 4D).
Treatment of diabetic groups with ALT-711 or AG pre-
vented the increase in skin collagen ﬂuorescence.
Atherosclerotic lesion collagen content. The total col-
lagen content in lesions was 10 times greater in the
untreated diabetic aortic lesions as compared with nondi-
abetic controls (Table 2). This was related to signiﬁcant
increases in each of the collagens studied, speciﬁcally
collagens I, III, and IV (Table 2). Treatment with ALT-711
attenuated the overall increase in plaque collagen content
by 50% but displayed differential effects on the three
types of collagen studied. The reduction with ALT-711
treatment was most profound for collagen IV, which was
normalized to nondiabetic levels, with collagen III attenu-
ated by 50%, whereas there was no effect on the increase
in type I collagen. AG completely abrogated the diabetes-
induced increase in total collagen, which was related in
part to reductions in each of the collagen subtypes (Table
2).
Collagen I was identiﬁed throughout the aortic wall and
within plaques of the diabetic apoE/ mice. ALT-711
seemed to reduce the collagen content of the wall only, in
contrast to AG, which provided no reduction in either
plaque or aortic wall content of collagen I. Collagen III was
localized to the outer layer of the elastic laminae through-
out the vessel wall of diabetic animals. There was also
staining perpendicular to the elastic laminae transversing
the aortic media. In addition, collagen III was evident in
the ﬁbrous cap of complex plaques. Neither ALT-711 nor
AG reduced the collagen III content immediately over
plaques, although there was signiﬁcant attenuation within
the vessel wall in each of the treatment groups. Collagen
IV was identiﬁed throughout the internal elastic laminae,
particularly toward the outer surface. These layers were
thickened in the diabetic apoE/ mice with collagen IV
deposition also evident within plaques. Both treatment
groups showed a reduction in the content of collagen IV
within the vessel wall and plaques, although the superﬁcial
surface staining of plaques remained unchanged.
Proﬁbrotic cytokines. Aortic CTGF protein expression
was induced by diabetes (Fig. 5A). CTGF mRNA and
protein were localized within aortic plaques and in the
FIG. 1. Morphometric quantiﬁcation of atherosclerotic plaque area in en face dissections of aortic segments (% aortic area: mean  SD). A: Total
aorta. B: Aortic arch. C: Thoracic aorta. D: Abdominal aorta. *P < 0.001 vs. control group; †P < 0.001 vs. diabetic group; ‡P < 0.001 vs. DALT
group; §P < 0.05 vs. diabetic group; #P < 0.05 vs. control group.
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ated these increases in CTGF gene and protein expression
to levels seen in control apoE/ mice. A similar pattern
was seen for TGF-1 expression, which was increased in
diabetic apoE/ aortas as compared with control mice
and was reduced in the treated groups (Fig. 5B).
-SMA. -SMA protein expression, as assessed by immu-
nohistochemistry, was increased in the aortas from un-
treated diabetic as compared with control mice (Fig. 5C).
This parameter was reduced by each of the treatments,
although not to control levels (Fig. 5C).
DISCUSSION
The present study has clearly demonstrated that two
disparate approaches to prevent aortic AGE accumula-
tion—with either an inhibitor of AGE formation, AG, or an
AGE cross-link breaker, ALT-711—are associated with
attenuation of plaque area in a model of diabetes-associ-
ated atherosclerosis. These effects occurred in the context
of reduced accumulation of AGEs within the aortas;
reduced expression of RAGE, which has been implicated
in the mediation of many of the biological effects of AGEs;
alterations in both AGEs and ALEs present on skin colla-
gen; and a reduction in the expression of prosclerotic
growth factors and extracellular collagenous proteins.
AGE accumulation in aortic atheroma has been previ-
ously identiﬁed in nondiabetic patients (29). The present
study conﬁrms that AGEs are increased in diabetic
apoE/ mice as reported by Park et al. (10). Increases in
aortic CML were found in association with increased CML
in skin collagen. Analysis of skin collagen AGEs provides
information about historical glycemic control as evi-
denced in type 1 diabetic patients in the Diabetes Control
and Complications Trial (30) and signiﬁcantly correlates
with the long-term macrovascular outcomes of these pa-
tients recently published for the Epidemiology of Diabetes
Interventions and Complications study (31), a follow-up
trial of Diabetes Control and Complications Trial subjects.
Recently, CML has been recognized as an ALE as well as
an AGE because it can be formed during either lipid or
carbohydrate oxidation (32). Thus, it may be that the
increased CML in the atherosclerotic plaques and walls of
the aortas observed in the present study is the result of
both glycoxidation and peroxidation of lipoproteins and
lipids. It is interesting that in the context of aortic plaque
reduction, the ALT-711 treatment group had a reduction in
plasma LDL cholesterol but lipid levels remained elevated.
Our data provide the ﬁrst report of the effects of ALT-711
on serum lipids, particularly in the apoE/ mouse.
Although in human trials, AG has demonstrated lipid-
FIG. 2. Measurements of advanced glycation. A: Plasma ﬂuorescence
of AGE peptides (Ex 370 nm, Em 440 nm; arbitrary units), B:
Morphometric quantiﬁcation of aortic CML immunostaining (%). C:
Morphometric quantiﬁcation of aortic RAGE immunostaining (%).
*P < 0.001 vs. control group; †P < 0.001 vs. diabetic group; ‡P < 0.005
vs. diabetic group.
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suggested that in rodents, AG has no or minimal effect on
plasma cholesterol and a modest effect on triglycerides
(8). This is consistent with the present study in which no
major effect of AG was demonstrated on the lipid proﬁle in
the diabetic apoE/ mice. Importantly, despite different
effects on lipids, both ALT-711 and AG were equally
effective in reducing aortic CML content. The relative role
of these agents on glycoxidation and lipoxidation in me-
diating their antiatherosclerotic effects remains to be
determined. These pathways need to be considered fur-
ther, however, with the recent demonstration that other
agents that inhibit AGE accumulation may also inﬂuence
lipid- and glucose-dependent pathways (8).
An important ﬁnding in the present study was the
regional efﬁcacy of the AGE inhibitors in attenuating
plaque formation. Whereas both ALT-711 and AG had no
signiﬁcant effects on atherosclerosis within the aortic
arch, previous studies by our own group using the same
model have shown that angiotensin-converting enzyme
(ACE) inhibition was effective in the aortic arch as well as
in the thoracic and abdominal regions of the aorta (16).
This suggests that the renin-angiotensin system (RAS),
speciﬁcally the local RAS rather than systemic blood
pressure, may be particularly important in plaque accumu-
lation within this region of the aorta, especially in the
context of a reduction in blood pressure by ALT-711,
without effects on plaque formation at this site. The effects
A E
F
G
H D
C
B
FIG. 3. Representative aortic immuno-
staining of CML for control (A), diabetic
(B), DALT (C), and DAG (D) and aortic
RAGE expression in control (Cont; E),
diabetic (Diab; F), DALT (G), and DAG
(H). Magniﬁcation 200.
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and abdominal aorta were similar to those seen with
perindopril. This suggests that metabolic pathways such
as AGE accumulation predominate at these sites. Further-
more, with the recent demonstration both in vitro and in
vivo that ACE inhibitors can act as potent inhibitors of
AGE formation (33,34), it is possible that the effects of
perindopril at these sites may be partly related to its ability
to reduce AGE levels.
A range of studies from other groups have clearly
deﬁned that agents that interrupt AGE pathways inﬂuence
the vascular tree. Administration of ALT-711 to aging
patients abrogated vascular dysfunction attributed to ves-
sel wall stiffening, in the absence of blood pressure
reduction (15). AG has also been shown to have beneﬁcial
effects on vessel elasticity and endothelial dysfunction (3).
Because AG is also an inhibitor of inducible nitric oxide
synthase (35), it is possible that some of the beneﬁcial
FIG. 4. Analysis of skin collagen. A: Time taken for 50% digestion with pepsin (area under the curve). B: Skin collagen CML content. C: Skin
collagen CEL content. D: Skin collagen ﬂuorescence (Ex 370 nm, Em 440 nm; arbitrary units/mg hydroxyproline). *P < 0.001 vs. control group;
†P < 0.001 vs. diabetic group; ‡P < 0.001 vs. DALT group; §P < 0.01 vs. control group; #P < 0.05 DALT vs. DAG group; ˆP < 0.05 vs. diabetic group.
TABLE 2
Aortic lesion collagen content at week 20
Parameters Control Diabetes
Diabetes 
ALT-711
Diabetes 
AG
n 20 20 20 20
Total aortic lesion collagen (%) 3.9 
 1.5 41.3 
 3.7* 19.5 
 3.5†‡ 7.1 
 1.3†§
Aortic collagen I (%) 2.2 
 0.8 4.5 
 0.8 3.9 
 0.5 4.1 
 0.9
Aortic collagen III (%) 0.9 
 0.3 5.6 
 0.6* 2.1 
 0.3† 1.3 
 0.2†
Aortic collagen IV (%) 2.7 
 0.3 5.8 
 0.8* 2.7 
 0.5† 2.4 
 0.3†
*P  0.001 vs. control group; †P  0.001 vs. diabetes group; ‡P  0.005 vs. control group; §P  0.05 vs. diabetes  ALT group; P  0.05 vs.
control group.
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genetic deﬁciencies in inducible nitric oxide synthase have
been shown to be protective against the development of
atheroma (36). Nevertheless, the ability of ALT-711 to
attentuate atherosclerotic plaque formation in the present
study and previous experiments documenting the efﬁcacy
of sRAGE in this model (37) emphasize that the predom-
inant antiatherosclerotic effect of AG is likely to be
mediated via its actions as an inhibitor of AGE formation.
ALT-711 and the related compound N-phenacylthiazo-
lium bromide (38) have been reported by investigators to
be AGE cross-link breakers capable of the promoting the
cleavage and removal of preformed AGEs (39). Indeed,
although previously demonstrated to be an AGE cross-link
breaker (12), ALT-711 has also been shown to reduce the
accumulation of CML (13), and this effect has been postu-
lated to be due to chelation of copper ions, thereby
reducing copper catalyzed glycoxidation (40,41). One must
be cautious about the interpretation of these in vitro data
as these authors also did not ﬁnd an effect of ALT-711 in
contrast to studies deﬁning its ability to cleave preformed
AGEs (12). Skin collagen from the diabetic apoE/ mice
was heavily cross-linked as assessed by a reduction in its
solubility in pepsin and an increase in ﬂuorescent AGE
content. Treatment of diabetic apoE/ mice with ALT-
711 or AG reversed this defect in solubility and reduced
the accumulation of AGEs. It is likely that the mechanism
of action of these two compounds in conferring these
effects differs. Although ALT-711 restores collagen solubil-
ity and reduces aortic and skin AGE accumulation, there
was only partial attenuation of the diabetes-induced in-
crease in aortic collagen content in this group. This was in
contrast to the DAG treatment group, which showed a
similar level of aortic collagen content to that seen in
control apoE/ mice. This suggests that AG may be
providing its beneﬁcial effects on aortic lesions by prevent-
ing both the deposition of vascular collagen and, subse-
quently, AGE cross-link formation. This is also supported
by the results of assessment of individual collagen sub-
types. It is interesting that neither drug removed collagen
localized at the luminal surface of the plaques. It is
tempting to speculate that this may be beneﬁcial to plaque
stability in light of recent evidence suggesting that colla-
gen ratios (42) and ﬁbromuscular cap composition (43) are
important contributors to plaque stability. sRAGE admin-
FIG. 5. Morphometric quantiﬁcation of aortic immunohistochemistry
(% proportional area) for CTGF (A), TGB (B), and -SMA (C). *P <
0.001 vs. control group; †P < 0.001 vs. diabetic group; ‡P < 0.05 vs.
DALT group; #P < 0.05 vs. control group.
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associated with less collagen accumulation (37).
The present study demonstrated a blood pressure–
lowering effect of ALT-711. This is consistent with
preliminary clinical data from the as-yet-unpublished
SILVER/SAPPHIRE trials in isolated systolic hyperten-
sion in which ALT-711 has conferred positive effects on
blood pressure, albeit it in a nondiabetic context (ww-
w.alteon.com). One cannot exclude a role for blood
pressure in the acceleration of atherosclerosis because
our group has previously shown beneﬁcial effects in the
diabetic apoE/ model with the ACE inhibitor perin-
dopril (16). Although this effect of the ACE inhibitor
has, in general, been interpreted as suggesting a role for
blockade of the RAS as the mediator of reduced aortic
plaque formation, a direct effect of ALT-711 on blood
pressure cannot be excluded. Nevertheless, AG also
attenuated atherosclerosis without affecting systemic
blood pressure. Furthermore, other studies have shown
that hypertension does not account for accelerated
atherosclerosis in apoE/ mice in association with
vascular dysfunction (44). Indeed, our own studies in
diabetic apoE/ mice that were treated with the
calcium channel blocker amlodipine have identiﬁed no
improvement in aortic lesions despite normalization of
blood pressure (45). In support of this observation,
studies by Miyata et al. (33) have also previously
demonstrated that nifedipine, another dihydropyridine
calcium channel blocker, has no effect on AGE forma-
tion.
A E
F
G
H D
C
B
FIG. 6. Representative aortic dark ﬁeld in
situ hybridization for CTGF. For control
(A), diabetes (B), DALT (C), and DAG
(D); and aortic CTGF protein visualized
by immunohistochemistry in control
(Cont; E), diabetes (Diab; E), DALT (G),
and DAG (H). Magniﬁcation 200.
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out the vessel wall and on the luminal side of plaques from
diabetic apoE/ mice. It is interesting that although the
increase in vascular collagen I accumulation was partially
abrogated by treatment with ALT-711, the plaque content
of collagen I remained unchanged. By contrast, AG atten-
uated the increases in both the aortic wall and the plaque
for collagen I. Furthermore, diabetes-induced increases in
collagen III and IV, although attenuated in the vascular
wall, were not reduced within plaques from treated ani-
mals. Because the presence of collagen within the plaques
may provide plaque stability (42), the region-speciﬁc de-
pletion of collagen I within the vessel wall but not within
the plaque itself by ALT-711, in contrast to depletion at
both sites by AG, may ultimately represent a potential
therapeutic advantage of ALT-711 over agents such as AG.
However, interpretation of these ﬁndings remains specu-
lative because this difference between agents was not
noted for all collagen subtypes. In addition, AGEs have
been shown to induce the proliferation (46) and activation
of vascular smooth muscle cells (47) to produce ﬁbrillar
collagen. This is supported in the present study by the
amelioration of diabetes-induced -SMA expression by
each of the AGE reducing treatments.
The proﬁbrotic cytokine CTGF was increased in the
atherosclerotic vessels and may be contributing to the
deposition of matrix proteins in the vasculature of these
diabetic apoE/ mice. Recent studies by our own group
have demonstrated increases in aortic CTGF in this exper-
imental model of atherosclerosis and diabetes (16). Fur-
thermore, we have previously shown that AG (26) and
ALT-711 (13) have the ability to reduce the expression of
CTGF in diabetic nephropathy. Therefore, the reduction in
CTGF expression in response to the inhibitors of AGE
accumulation as demonstrated in the present study was
not surprising. These ﬁndings provide further evidence for
the view that this growth factor plays a pivotal role in
mediating collagen deposition in various contexts, includ-
ing diabetes.
RAGE has been identiﬁed as a modulator of inﬂamma-
tion (48) and as a major contributor to atherogenesis (10);
therefore, not surprisingly, diabetes increased the expres-
sion of RAGE in the vascular wall in apoE/ mice. The
reduction in aortic RAGE expression that was seen after
ALT-711 or AG treatment has also been reported after
administration of sRAGE in this same model (10). In all of
these studies, the various treatments were associated with
a reduction in atherosclerosis. It remains to be determined
whether the reduction in RAGE is just a manifestation of
less vascular disease or represents a central mechanism
for mediating the antiatherosclerotic effects of different
treatments that modulate the advanced glycation pathway.
The beneﬁts of sRAGE in this model have been interpreted
as indicative of the direct participation of RAGE in the
development of diabetes-associated atherosclerosis. How-
ever, an alternative interpretation of the results is that
sRAGE is acting primarily as a ligand to bind AGEs,
thereby promoting their removal and preventing their
interaction with other receptors to promote vascular in-
jury. RAGE also acts as a receptor to other inﬂammatory
molecules such as S-100, which may also promote athero-
sclerosis (48). However, the ﬁndings of the present study
emphasize the beneﬁts of blocking AGE accumulation per
se and are consistent with a mechanism whereby sRAGE
confers antiatherosclerotic effects via suppression of
AGE-mediated pathways. The recent advent of a viable
RAGE knockout mouse will greatly facilitate further elu-
cidation of the speciﬁc role of RAGE in this ﬁeld (49).
The present study has identiﬁed that AGEs play an
important role in diabetes-associated atherosclerosis, be-
cause ALT-711 and AG both were effective in reducing
both atherosclerotic plaque formation and complexity.
These ﬁndings extend our understanding of the central
role of AGEs in atherosclerosis, particularly in the diabetic
context, and provide clinical investigators with an increas-
ing number of therapeutic options to explore as part of the
approach to reduce the burden of cardiovascular disease
in diabetes.
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